Table 1 Characteristics of COVID-19 patients in observational cohort
Total (N = 682) | No treatment (N = 155) | Steroids (N = 324) | Steroids and IL-6 inhibitors (N = 201) | P-value | |
|---|---|---|---|---|---|
Age (yrs) | 64 [56–72] | 65 [56–73] | 64 [56–72] | 62 [55–72] | 0.57 |
Male, n (%) | 492 (72.1) | 117 (75.5) | 242 (74.7) | 133 (66.2) | 0.06 |
BMI | 29 [26–33] | 29 [26–32] | 29 [26–33] | 29 [26–33] | 0.29 |
Co-morbidity | |||||
DM n, (%) | 207 (30.4) | 52 (33.5) | 104 (32.1) | 50 (24.9) | 0.13 |
Hypertension n, (%) | 245 (35.9) | 44 (28.4) | 132 (40.7) | 68 (33.8) | 0.02 |
Heart failure n, (%) | 24 (3.5) | 10 (6.5) | 8 (2.5) | 6 (3.0) | 0.08 |
CAD n, (%) | 101 (14.8) | 27 (17.4) | 46 (14.2) | 27 (13.5) | 0.55 |
Medication use on admission | |||||
PLT inhibitors n, (%) | 127 (18.6) | 28 (18.1) | 61 (18.8) | 38 (19.0) | 0.97 |
Anticoagulants n, (%) | 216 (31.7) | 41 (26.5) | 110 (34.0) | 65 (32.5) | 0.25 |
Disease severity | |||||
APACHE III | 61 [49–75] | 60 [47–77] | 62 [51–76] | 60 [49–74] | 0.48 |
SOFA | 6 [4–8] | 6 [4–7] | 6 [4–8] | 7 [4–8] | 0.82 |
IMV n, (%) | 513 (75.2) | 113 (72.9) | 251 (77.5) | 148 (73.6) | 0.45 |
Vasopressor > 2 days n, (%) | 341 (50.0) | 79 (51.0) | 158 (48.8) | 104 (51.7) | 0.80 |
Lab on ICU admission | |||||
Hb (g/dl) | 12.1 [10.8–13.2] | 11.4 [10.2–12.6] | 12.2 [10.8–13.2]* | 12.6 [11.4–13.5]* | < 0.001 |
CRP (mg/L) | 104 [52–179] | 167 [88–220] | 91 [43–162]* | 84 [57–164]* | < 0.001 |
LDH (U/L) | 409[324–512] | 395[300–508] | 405[324–501] | 430[342–532] | 0.046 |